107.53
+0.31(+0.29%)
Currency In USD
| Previous Close | 107.22 |
| Open | 106.15 |
| Day High | 108.9 |
| Day Low | 106.15 |
| 52-Week High | 139.13 |
| 52-Week Low | 64.11 |
| Volume | 542,917 |
| Average Volume | 774,620 |
| Market Cap | 5.29B |
| PE | -18.64 |
| EPS | -5.77 |
| Moving Average 50 Days | 111.97 |
| Moving Average 200 Days | 100.17 |
| Change | 0.31 |
If you invested $1000 in Axsome Therapeutics, Inc. (AXSM) since IPO date, it would be worth $12,303.2 as of May 16, 2025 at a share price of $107.53. Whereas If you bought $1000 worth of Axsome Therapeutics, Inc. (AXSM) shares 5 years ago, it would be worth $1,260.91 as of May 16, 2025 at a share price of $107.53.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone
GlobeNewswire Inc.
May 13, 2025 11:00 AM GMT
Previous term loan facility retired NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that
Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month
GlobeNewswire Inc.
May 01, 2025 11:00 AM GMT
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is joining with Mental Health America
Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5
GlobeNewswire Inc.
Apr 08, 2025 11:00 AM GMT
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results fo